Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 10/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.40 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.38 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.38 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.38 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714613 | 0.88 | CD38 (0.40) | SLC6A5CD38 | |
| SCHEMBL30714713 | 0.86 | HTR3A (0.51) | SLC6A5HTR3A | |
| SCHEMBL30714662 | 0.82 | CYP11B2 (0.33) | HTR3A | |
| SCHEMBL30714614 | 0.82 | GUCY1B2 (0.40) | SLC6A5CHRNB2CHRNA4GUCY1B2GUCY1A2 | |
| SCHEMBL30714756 | 0.82 | HPGDS (0.43) | RAB9A | |
| SCHEMBL30714709 | 0.81 | SSTR4 (0.43) | SLC6A5CHRNB2CHRNA4GUCY1B2GUCY1A2 | |
| SCHEMBL30714689 | 0.81 | HPGDS (0.35) | HTR3A | |
| SCHEMBL30714618 | 0.81 | SCN9A (0.37) | HTR3A | |
| SCHEMBL30714550 | 0.80 | KDM4E (0.46) | SLC6A5HTR3ADRD4 | |
| SCHEMBL26696010 | 0.79 | HPGDS (0.41) | KCNH2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SLC6A5 904/4885CHRNB2 482/4885CHRNA4 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.